Manganese in human parenteral nutrition: Considerations for toxicity and biomonitoring

Dinamene Santos; Camila Batoreu; Luisa Mateus; A. P. Marreilha dos Santos; Michael Aschner

doi:10.1016/j.neuro.2013.10.003

Manganese in human parenteral nutrition: Considerations for toxicity and biomonitoring

Dinamene Santos, Camila Batoreu, Luisa Mateus, A. P. Marreilha dos Santos, Michael Aschner

Research output: Contribution to journal › Article › peer-review

62 Scopus citations

Abstract

The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk.

Original language	English (US)
Pages (from-to)	36-45
Number of pages	10
Journal	Neurotoxicology
Volume	43
DOIs	https://doi.org/10.1016/j.neuro.2013.10.003
State	Published - Jul 2014
Externally published	Yes

Keywords

Biomonitoring
Manganese
Neurotoxicity
Parenteral nutrition

ASJC Scopus subject areas

General Neuroscience
Toxicology

Access to Document

10.1016/j.neuro.2013.10.003

Cite this

@article{bc0c632893bf490b935ec9e880c9c7e7,

title = "Manganese in human parenteral nutrition: Considerations for toxicity and biomonitoring",

abstract = "The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk.",

keywords = "Biomonitoring, Manganese, Neurotoxicity, Parenteral nutrition",

author = "Dinamene Santos and Camila Batoreu and Luisa Mateus and {Marreilha dos Santos}, {A. P.} and Michael Aschner",

note = "Funding Information: The authors acknowledge FCT (Foundation for Science and Technology of Portugal ; SFRH/BD/64128/2009) and the National Institute of Environmental Health Sciences (ES R01 10563 (MA)). ",

year = "2014",

month = jul,

doi = "10.1016/j.neuro.2013.10.003",

language = "English (US)",

volume = "43",

pages = "36--45",

journal = "Neurotoxicology",

issn = "0161-813X",

publisher = "Elsevier",

}

TY - JOUR

T1 - Manganese in human parenteral nutrition

T2 - Considerations for toxicity and biomonitoring

AU - Santos, Dinamene

AU - Batoreu, Camila

AU - Mateus, Luisa

AU - Marreilha dos Santos, A. P.

AU - Aschner, Michael

N1 - Funding Information: The authors acknowledge FCT (Foundation for Science and Technology of Portugal ; SFRH/BD/64128/2009) and the National Institute of Environmental Health Sciences (ES R01 10563 (MA)).

PY - 2014/7

Y1 - 2014/7

N2 - The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk.

AB - The iatrogenic risks associated with excessive Mn administration in parenteral nutrition (PN) patients are well documented. Hypermanganesemia and neurotoxicity are associated with the duration of Mn supplementation, Mn dosage, as well as pathological conditions, such as anemia or cholestasis. Recent PN guidelines recommend the biomonitoring of patients if they receive Mn in their PN longer than 30 days. The data in the literature are conflicting about the method for assessing Mn stores in humans as a definitive biomarker of Mn exposure or induced-neurotoxicity has yet to be identified. The biomonitoring of Mn relies on the analysis of whole blood Mn (WB Mn) levels, which are highly variable among human population and are not strictly correlated with Mn-induced neurotoxicity. Alterations in dopaminergic (DAergic) and catecholaminergic metabolism have been studied as predictive biomarkers of Mn-induced neurotoxicity. Given these limitations, this review addresses various approaches for biomonitoring Mn exposure and neurotoxic risk.

KW - Biomonitoring

KW - Manganese

KW - Neurotoxicity

KW - Parenteral nutrition

UR - http://www.scopus.com/inward/record.url?scp=84905913822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905913822&partnerID=8YFLogxK

U2 - 10.1016/j.neuro.2013.10.003

DO - 10.1016/j.neuro.2013.10.003

M3 - Article

C2 - 24184781

AN - SCOPUS:84905913822

SN - 0161-813X

VL - 43

SP - 36

EP - 45

JO - Neurotoxicology

JF - Neurotoxicology

ER -

Manganese in human parenteral nutrition: Considerations for toxicity and biomonitoring

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this